U.S. Software Stock News

Safety Insurance Group (SAFT) has wrapped up FY 2025 with Q4 revenue of US$319.3 million and basic EPS of US$1.37, rounding out a year in which trailing twelve month revenue reached about US$1.26 billion and EPS came in at US$6.75. Over recent quarters, the company has seen revenue move from US$286.7 million and EPS of US$0.55 in Q4 2024 to the latest Q4 2025 levels. The trailing net profit margin of 7.9% sits above the 6.3% recorded a year earlier, setting up a results season where higher...

Salesforce FY 2026 earnings snapshot Salesforce (CRM) has just wrapped up FY 2026 with Q4 revenue of US$11.2b and basic EPS of US$2.08, setting the tone for a year where investors are watching how top line scale and per share profitability move together. The company has seen quarterly revenue move from US$9.8b in Q1 FY 2026 to US$11.2b in Q4, with basic EPS ranging from US$1.61 to US$2.20 over the same stretch. Trailing 12 month revenue reached US$41.5b and EPS came in at US$7.85. Taken...

If you are wondering whether Huron Consulting Group shares are attractively priced or asking too much, you are in the right place for a clear look at value. The stock most recently closed at US$143.29, with returns of 9.4% over 7 days, a 15.7% decline over 30 days, a 16.2% decline year to date, and a 4.2% decline over 1 year, set against a 73.0% return over 3 years and 174.7% over 5 years. Recent news around Huron has focused on its role as a consulting partner helping organizations handle...

In February 2026, Larimar Therapeutics announced that the FDA granted Breakthrough Therapy Designation to nomlabofusp for treating adults and children with Friedreich’s ataxia, while the company advanced plans for an accelerated Biologics License Application supported by skin frataxin as a novel surrogate endpoint. This combination of expedited regulatory status and FDA alignment on using a new biomarker underscores how central nomlabofusp has become to Larimar’s clinical and regulatory...

Vaxart (VXRT) is drawing fresh attention ahead of its scheduled presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026. Investors will be listening for pipeline and funding updates. See our latest analysis for Vaxart. Vaxart’s recent 34.83% 7 day share price return and 102.97% 90 day share price return point to building momentum ahead of the conference, even as the 5 year total shareholder return of 87.31% highlights longer term challenges. If...

MercadoLibre FY 2025 earnings snapshot MercadoLibre (MELI) has wrapped up FY 2025 with fourth quarter revenue of US$8.8b and basic EPS of US$11.03, alongside net income of US$559m, putting fresh numbers behind the recent share price of US$1,740.88. The company has seen quarterly revenue move from US$6.1b and EPS of US$12.60 in Q4 2024 to US$8.8b and EPS of US$11.03 in Q4 2025, while trailing twelve month EPS sits at US$39.39 on revenue of US$28.9b. This gives investors a basis to weigh high...

PicS N.V. completed a US$434.3 million initial public offering. The company began trading on the Nasdaq Global Select Market under the ticker NasdaqGS:PICS. This is the first new stock listing by a Brazilian company in over four years. With its IPO now complete, PicS enters the public markets at a share price of $17.76 and a recent 7 day return of 17.6%. The listing of NasdaqGS:PICS also marks a return of Brazilian issuers to international equity markets after a multi year pause in new...

International General Insurance Holdings (IGIC) has put income front and center by declaring an extraordinary cash dividend of $1.15 per share, payable on April 6, 2026, to shareholders of record on March 18. See our latest analysis for International General Insurance Holdings. The extraordinary and ordinary dividends, along with the recently completed US$8.09 million buyback, come after a period where the share price has moved steadily rather than sharply. The 30 day share price return is...

Terns Pharmaceuticals (TERN) has drawn attention after recent trading, with the stock closing at US$40.92. For investors, the clinical stage focus on oncology and obesity raises questions about how current pricing reflects trial progress and cash needs. See our latest analysis for Terns Pharmaceuticals. While the share price slipped around 1% on the day to US$40.92, it remains on a strong short term run, with a 16.61% 1 month share price return and a 45.57% 3 month share price return,...

LifeStance Health Group (LFST) capped FY 2025 with fourth quarter revenue of US$382.2 million and basic EPS of US$0.03, while trailing twelve month revenue reached about US$1.4 billion with basic EPS of US$0.03. The company has seen revenue move from US$325.5 million in Q4 FY 2024 to US$382.2 million in Q4 FY 2025, alongside a shift in quarterly basic EPS from a loss of US$0.02 to a profit of US$0.03. This places improving profitability metrics at the center of the current earnings...

Crescent Energy (CRGY) closed FY 2025 with fourth quarter revenue of US$865.0 million and a small net loss of US$8.7 million, which translated into EPS of US$0.03 loss per share, while trailing 12 month revenue stood at about US$3.6 billion with net income of US$132.9 million and EPS of US$0.51. Over recent periods, revenue has ranged from US$744.9 million to US$950.2 million a quarter, with quarterly EPS swinging between a US$0.70 loss and a US$0.61 profit, so the latest numbers land in the...

National Storage Affiliates Trust (NYSE:NSA) reported solid Q4 operational progress, including better occupancy metrics and revenue trends across most markets. The company completed the consolidation of another brand, aiming to simplify its platform and improve operational consistency. NSA continued to refine its portfolio through asset sales, new acquisitions and joint ventures, while keeping liquidity conditions supportive of these moves. For investors tracking NYSE:NSA, the recent...

Churchill Downs (CHDN) has wrapped up FY 2025 with fourth quarter revenue of US$665.9 million and basic EPS of US$0.71, alongside trailing twelve month revenue of US$2.9 billion and EPS of US$5.36. The company has seen quarterly revenue move from US$624.2 million in Q4 2024 to US$665.9 million in Q4 2025, while basic EPS shifted from US$0.99 to US$0.71 over the same period. This sets up a contrast with a trailing net margin of 13.1% versus 15.6% a year earlier, which keeps investor attention...

If you are wondering whether J&J Snack Foods is starting to look attractively priced, you are not alone. This article will help you make sense of where the stock stands today. The shares last closed at US$85.11, with returns of 0.0% over 7 days, a 9.7% decline over 30 days, a 6.0% decline year to date, and a 33.6% decline over 1 year that sits against a 36.5% decline over 3 years and a 39.4% decline over 5 years. These moves have kept J&J Snack Foods on the radar for investors looking at...

ACADIA Pharmaceuticals (ACAD) capped FY 2025 with Q4 revenue of US$284 million and basic EPS of US$1.62, while trailing 12 month revenue reached about US$1.1 billion and basic EPS came in at US$2.32 as the company reported net profit margins of 36.5% over the last year, up from 23.6% the prior year. Over the past year, ACADIA has seen earnings grow 72.7% with a 5 year average earnings growth rate of 66.5% per year, and analysts currently expect earnings to grow about 8.2% per year alongside...

Nu Holdings (NYSE:NU) has capped FY 2025 with fourth quarter revenue of US$2.1b and basic EPS of US$0.18, while trailing twelve month revenue sits at US$7.0b with EPS of US$0.59, underscoring a period where earnings grew 45.5% over the past year and are forecast to grow about 26.4% per year over the next three years. Over recent periods, the company has seen revenue move from US$5.5b and EPS of US$0.41 on a trailing basis in Q4 2024 to US$7.0b and EPS of US$0.59 by Q4 2025, alongside a...

Disc Medicine (NasdaqGM:IRON) received a Complete Response Letter from the FDA for its bitopertin candidate for erythropoietic protoporphyria, shifting the drug to a traditional approval pathway. The company now plans to rely on its ongoing APOLLO Phase III trial as the core data package for future regulatory submissions. Management expects APOLLO to reach full enrollment soon, making the trial a key focus for the bitopertin program. For you as an investor, this update centers on how Disc...

If you are wondering whether Rigetti Computing's recent share price puts it above or below a reasonable value, you are not alone. This article is designed to help you frame that question clearly. Rigetti's stock closed at US$18.64, with a 17.1% return over the past week, a 15.3% decline over the past month, a 21.0% decline year to date, and a 120.3% return over the past year. These moves may leave you questioning whether the current price reflects opportunity or higher risk. Recent news...

Sterling Infrastructure (STRL) has wrapped up FY 2025 with fourth quarter revenue of US$755.6 million and basic EPS of US$2.85, alongside net income of US$87.6 million, setting a clear marker for how the year finished. Over the past six quarters, the company has seen quarterly revenue move from US$498.8 million in Q4 2024 to US$755.6 million in Q4 2025, while basic EPS shifted from US$3.69 to US$2.85 and trailing twelve month EPS went from US$5.98 in Q3 2024 to US$9.50 in Q4 2025, giving...

Kinetik Holdings (KNTK) has just posted its FY 2025 numbers, with Q4 revenue of US$430.4 million and basic EPS of US$2.24, capping a year in which trailing twelve month revenue reached about US$1.8 billion and basic EPS came in at US$2.88. Over the past few reported periods, the company has seen quarterly revenue range from US$426.7 million to US$464.0 million and basic EPS move between roughly US$0.03 and US$2.24. Trailing net profit margins recently sat at 10.1% versus 4.1% a year earlier...

Perfect Corp. recently announced a partnership with True Beauty Lashes to power LashLovr™, an AI-driven lash matching and virtual try-on experience that uses its Virtual Try-On and Face Analyzer APIs to help shoppers find better-fitting false lashes in real time. This collaboration highlights how Perfect’s pay-as-you-go AI and AR APIs can lower adoption hurdles for beauty brands while showcasing a concrete, research-backed use case that could support broader B2B uptake of its technology...

How OneStream (OS) Has Been Trading Recently With no single headline event driving OneStream (OS) today, investors are instead weighing its recent share performance, revenue profile, and current losses to assess how the stock fits into their software exposure. See our latest analysis for OneStream. At a recent share price of $23.60, OneStream sits on a 90 day share price return of 13.3% and a year to date share price return of 33.18%, while the 1 year total shareholder return is 3.1%. This...

The Morning Bull - US Market Morning Update Friday, Feb, 27 2026 US stock futures are pointing slightly lower this morning, with E-mini S&P 500 futures down about 0.2%, as investors weigh cheaper borrowing costs against mixed global growth signals. The 30 year US mortgage rate has dipped below 6% to 5.98%, which can make monthly payments a bit less painful and puts housing related names in focus. At the same time, the Kansas Fed Manufacturing Index has bounced to 10, a sign that factory...

Soleno Therapeutics (SLNO) just closed out FY 2025 with fourth quarter revenue of US$91.7 million and basic EPS of US$0.81, alongside net income of US$42.9 million. This capped a trailing 12 month line that shows revenue of US$190.4 million and basic EPS of US$0.40. The company reported revenue of US$66.0 million in Q3 and US$32.7 million in Q2, while EPS moved from US$0.49 in Q3 and a small loss in Q2. Together, these figures describe a story where higher sales and a cleaner income line are...